Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (11-20 of 204) with videos related to

Pageof 21
Sort By:
Lancet (London, England)|May 15, 2017
J-ALEX: alectinib versus crizotinib in ALK-positive lung cancerJustin F Gainor, Alice T Shaw
Cancer|April 11, 2012
Hypogonadism related to crizotinib therapy: implications for patient careSuresh S Ramalingam, Alice T Shaw
Clinical Advances in Hematology & Oncology : H&O|October 17, 2014
ALK inhibitors in non-small cell lung cancer: crizotinib and beyondMark M Awad, Alice T Shaw
Cancer Discovery|June 11, 2013
The new kid on the block: RET in lung cancerJustin F Gainor, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2012
Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?Adam S Crystal, Alice T Shaw
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
New targets in advanced NSCLC: EML4-ALKAdam S Crystal, Alice T Shaw
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationAlice T Shaw, Jeffrey A Engelman
The Oncologist|July 2, 2013
Novel targets in non-small cell lung cancer: ROS1 and RET fusionsJustin F Gainor, Alice T Shaw
Nature Reviews. Clinical Oncology|November 9, 2017
Tumour heterogeneity and resistance to cancer therapiesIbiayi Dagogo-Jack, Alice T Shaw
Ebiomedicine|February 10, 2019
Refining precision cancer therapy in ALK-positive NSCLCJessica J Lin, Alice T Shaw
Pageof 21

Showing results (11-20 of 204) with videos related to

Sort By:
Pageof 21
Lancet (London, England)|May 15, 2017
J-ALEX: alectinib versus crizotinib in ALK-positive lung cancerJustin F Gainor, Alice T Shaw
Cancer|April 11, 2012
Hypogonadism related to crizotinib therapy: implications for patient careSuresh S Ramalingam, Alice T Shaw
Clinical Advances in Hematology & Oncology : H&O|October 17, 2014
ALK inhibitors in non-small cell lung cancer: crizotinib and beyondMark M Awad, Alice T Shaw
Cancer Discovery|June 11, 2013
The new kid on the block: RET in lung cancerJustin F Gainor, Alice T Shaw
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2012
Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?Adam S Crystal, Alice T Shaw
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
New targets in advanced NSCLC: EML4-ALKAdam S Crystal, Alice T Shaw
The New England Journal of Medicine|May 5, 2016
Crizotinib Resensitization by Compound MutationAlice T Shaw, Jeffrey A Engelman
The Oncologist|July 2, 2013
Novel targets in non-small cell lung cancer: ROS1 and RET fusionsJustin F Gainor, Alice T Shaw
Nature Reviews. Clinical Oncology|November 9, 2017
Tumour heterogeneity and resistance to cancer therapiesIbiayi Dagogo-Jack, Alice T Shaw
Ebiomedicine|February 10, 2019
Refining precision cancer therapy in ALK-positive NSCLCJessica J Lin, Alice T Shaw
Pageof 21